CAMBRIDGE, Massachusetts, March 31, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody ...
Zacks Investment Research on MSN
All you need to know about Promis Neurosciences (PMN) rating upgrade to buy
Promis Neurosciences (PMN) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- ...
ProMIS Neurosciences Inc., a biotechnology company focused on developing antibody therapeutics for neurodegenerative diseases, announced progress in its clinical programs and shared insights from its ...
Hosted on MSN
Wall Street analysts think Promis Neurosciences (PMN) could surge 231.78%: Read this before placing a bet
Promis Neurosciences (PMN) closed the last trading session at $10.7, gaining 1.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by ...
View ProMIS Neurosciences Inc. PMN stock quote prices, financial information, real-time forecasts, and company news from CNN.
ProMIS Neurosciences Inc., a clinical-stage biotechnology firm, announced its plan to present preclinical data on novel computationally-derived vaccines targeting neurodegenerative diseases at the ...
Social determinants of health and utilization of neoadjuvant chemotherapy in patients with triple negative breast cancer (TNBC) in the community oncology setting. The proliferation biomarker SPAG5 ...
"2024 was a transformational year for ProMIS Neurosciences as we reached a major milestone with the initiation of our 100-patient Phase 1b clinical trial for PMN310, our lead antibody candidate for AD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results